Who Are We?
Since there is currently no cure for metastatic disease, the importance of locating advanced and innovative drugs and treatments worldwide has become of immense significance, bringing great hope to patients. The National Cancer Institute (NCI), the National Comprehensive Cancer Network (NCCN), and the American Society of Clinical Oncology (ASCO) emphasize that the best treatment a cancer patient can receive is through participation in a clinical trial. Unequivocally. There, the chance of extending life significantly exceeds the chance with standard treatment. This is the progress in cancer medicine, and it is here and now:
Nir Erez's and Trial-In Pharma's vision is to break boundaries and cure Stage IV cancer patients, which is metastatic cancer or aggressive brain cancer that does not spread distant metastases.
Trial-In Pharma is a medical company in the field of cancer and the only one that performs a unique, personalized examination that reveals innovative and breakthrough oncology drugs and treatments, and subsequently accompanies these patients. This includes cases of metastatic cancer, rare or aggressive cancer, or brain cancer patients.
Trial-In Pharma was established in mid-2016 by Nir Erez, the company's CEO, following an oncology publication he encountered showing highly impressive interim results from a clinical trial with a new drug. Had he known about the study and the drug in time, he would have acted to enroll his mother in it while she was still alive. Within the healthcare system, the doctors were unaware of the study and the drug. The research was taking place in other countries in Europe and the USA.
With this understanding, Erez founded Trial-In Pharma with the goal that cancer patients receive tomorrow's treatments today—treatments that are currently only possible within the framework of clinical trials or drugs in research and development, but which in a few years will become the accepted standard of care as they prove to be more effective and no less safe than today's treatments. With approximately 20,000 clinical trials in cancer open for patient recruitment worldwide, there are many treatment options that must be screened and personalized for each and every patient.
What Characterizes Us?
- ✓ A strong desire to leave no stone unturned, searching for and bringing the "Golden Flower" to every cancer patient locally and globally.
- ✓ Professional experience in the field of oncology and medical cancer research for over 20 years.
- ✓ A team of 17 senior oncologists and clinical research professionals.
- ✓ Access to accurate global databases and international professional oncology literature.
- ✓ Strong connections with senior oncologists worldwide and with pharmaceutical companies.
- ✓ We are experts in Stage 4 metastatic cancer, or cases of rare, aggressive cancer, or patients with brain tumors.
Which Cases Have We Supported So Far?
To date (January 2026), we have supported over 25,000 patients and family members.
From Israel, the United States, Greece, England, Russia, Italy, Poland, Germany, South American countries such as Peru, Brazil, Paraguay, Argentina, and Uruguay.
The cases we have supported so far include Stage 3b cancer, Stage 4 metastatic cancer, and various brain tumors.
